FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to evaluate the immunogenicity along with safety and
toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine
(Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint
inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular
carcinoma (FL-HCC) or other cancer entities carrying the DNAJB1-PRKACA fusion transcript.